Dermata Therapeutics Inc (DRMA)

$2.25 -0.56 (-19.93%)
Market Cap 2.88M
Revenue (ttm) 0.00
Net Income (ttm) -12.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 979,300
Avg Vol 1,789,032
Day's Range N/A - N/A
Shares Out 1.03M
Stochastic %K 9%
Beta 0.54
Analysts Strong Sell
Price Target $10.00

Company Profile

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 800 2543
Address:
3525 Del Mar Heights Rd., Suite 332, San Diego, United States
spinooch
spinooch Jan. 30 at 11:19 PM
$DRMA thanks to whoever bought my Tammy bag at $2.80 this morning. She should market those: "Tammy Bags, inspired by Front Loading". She would do well.
1 · Reply
FuPayMee
FuPayMee Jan. 30 at 10:11 PM
$DRMA $DRCT
0 · Reply
Ms_Scammy121
Ms_Scammy121 Jan. 30 at 9:31 PM
$DRMA let's gooooooo new lows!!!!
1 · Reply
yaycapitalism
yaycapitalism Jan. 30 at 9:13 PM
$DRMA Me likey.
0 · Reply
HolEKa1010
HolEKa1010 Jan. 30 at 9:02 PM
$DRMA why are all of Tam Tam people who just recently bought in freaking out?😂 u aren’t helping the rest of us…
1 · Reply
tildo92
tildo92 Jan. 30 at 8:50 PM
$DRMA guys I bought at 16.000 SP do you think it will Go back? ^^
0 · Reply
Paperhander
Paperhander Jan. 30 at 8:06 PM
$DRMA Wow I bought 100 she amd caused it to go up .02
0 · Reply
fisher04
fisher04 Jan. 30 at 7:49 PM
$DRMA loaded at 2.30$ .
0 · Reply
Ms_Scammy121
Ms_Scammy121 Jan. 30 at 7:12 PM
$DRMA did tam tam get you guys again?? Lolllll
3 · Reply
SaltWaterChickens
SaltWaterChickens Jan. 30 at 6:55 PM
$DRMA on the 👇🏻 but with patience
0 · Reply
Latest News on DRMA
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

Jan 20, 2026, 8:05 AM EST - 10 days ago

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 29, 2025, 4:05 PM EST - 4 weeks ago

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 24, 2025, 8:00 AM EST - 5 weeks ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

Dec 4, 2025, 8:00 AM EST - 2 months ago

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:05 PM EST - 2 months ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Oct 2, 2025, 8:00 AM EDT - 4 months ago

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Sep 17, 2025, 1:00 AM EDT - 4 months ago

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Sep 16, 2025, 8:35 AM EDT - 4 months ago

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Sep 10, 2025, 8:00 AM EDT - 5 months ago

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 5:00 PM EDT - 6 months ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jul 8, 2025, 8:00 AM EDT - 7 months ago

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025, 9:00 AM EDT - 9 months ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Apr 15, 2025, 8:30 AM EDT - 10 months ago

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025, 8:15 PM EDT - 11 months ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Mar 27, 2025, 10:21 AM EDT - 11 months ago

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Mar 27, 2025, 9:57 AM EDT - 11 months ago

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 27, 2025, 8:00 AM EDT - 11 months ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Mar 17, 2025, 4:16 PM EDT - 11 months ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Mar 4, 2025, 8:03 AM EST - 11 months ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Feb 25, 2025, 7:58 AM EST - 1 year ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata to Present on BioPub on January 31, 2025

Jan 29, 2025, 4:05 PM EST - 1 year ago

Dermata to Present on BioPub on January 31, 2025

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Jan 28, 2025, 4:05 PM EST - 1 year ago

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 23, 2025, 4:15 PM EST - 1 year ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025, 8:00 AM EST - 1 year ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Jan 21, 2025, 8:00 AM EST - 1 year ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 16, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 10, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dec 3, 2024, 9:00 AM EST - 1 year ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:15 PM EST - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Nov 11, 2024, 8:35 AM EST - 1 year ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Oct 8, 2024, 4:15 PM EDT - 1 year ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 17, 2024, 5:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024, 9:00 PM EDT - 1 year ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

May 17, 2024, 8:30 AM EDT - 1 year ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Mar 27, 2024, 4:05 PM EDT - 2 years ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Mar 21, 2024, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Feb 1, 2024, 9:00 AM EST - 2 years ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Jan 4, 2024, 4:05 PM EST - 2 years ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dec 20, 2023, 4:05 PM EST - 2 years ago

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 1:30 PM EST - 2 years ago

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Nov 16, 2023, 8:00 AM EST - 2 years ago

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:05 PM EST - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 31, 2023, 9:00 AM EDT - 2 years ago

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

Jun 27, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

spinooch
spinooch Jan. 30 at 11:19 PM
$DRMA thanks to whoever bought my Tammy bag at $2.80 this morning. She should market those: "Tammy Bags, inspired by Front Loading". She would do well.
1 · Reply
FuPayMee
FuPayMee Jan. 30 at 10:11 PM
$DRMA $DRCT
0 · Reply
Ms_Scammy121
Ms_Scammy121 Jan. 30 at 9:31 PM
$DRMA let's gooooooo new lows!!!!
1 · Reply
yaycapitalism
yaycapitalism Jan. 30 at 9:13 PM
$DRMA Me likey.
0 · Reply
HolEKa1010
HolEKa1010 Jan. 30 at 9:02 PM
$DRMA why are all of Tam Tam people who just recently bought in freaking out?😂 u aren’t helping the rest of us…
1 · Reply
tildo92
tildo92 Jan. 30 at 8:50 PM
$DRMA guys I bought at 16.000 SP do you think it will Go back? ^^
0 · Reply
Paperhander
Paperhander Jan. 30 at 8:06 PM
$DRMA Wow I bought 100 she amd caused it to go up .02
0 · Reply
fisher04
fisher04 Jan. 30 at 7:49 PM
$DRMA loaded at 2.30$ .
0 · Reply
Ms_Scammy121
Ms_Scammy121 Jan. 30 at 7:12 PM
$DRMA did tam tam get you guys again?? Lolllll
3 · Reply
SaltWaterChickens
SaltWaterChickens Jan. 30 at 6:55 PM
$DRMA on the 👇🏻 but with patience
0 · Reply
fullFLT
fullFLT Jan. 30 at 5:54 PM
$DRMA Looks like those that needed out got out … ( thank you ) This is way oversold markets all down she will be just fine
0 · Reply
kaefer
kaefer Jan. 30 at 5:38 PM
$DRMA The weekly candles show we‘re still at the bottom, but going up from here.
0 · Reply
Ibri
Ibri Jan. 30 at 5:35 PM
$DRMA Thanks for cheapies
0 · Reply
Octokuro
Octokuro Jan. 30 at 5:33 PM
$DRMA They just released a SEC on 29th Jan. The prospectus registers up to 6,207,730 shares and warrant-related shares for resale. The selling stockholders can begin selling the registered shares in the open market. This is going down to the $2.04 per share of common stock or equivalent instrument (including pre-funded warrants).
0 · Reply
Bazzzigar
Bazzzigar Jan. 30 at 5:31 PM
$DRMA RXRX
0 · Reply
ericsb
ericsb Jan. 30 at 5:25 PM
$DRMA bought back in for this dip. Hoping for a rebound towards close.
0 · Reply
jtfunny
jtfunny Jan. 30 at 5:15 PM
$DRMA where’s @MS_Tammy ?
1 · Reply
fullFLT
fullFLT Jan. 30 at 5:15 PM
$DRMA 🤗
0 · Reply
TravisBking87
TravisBking87 Jan. 30 at 5:08 PM
$DRMA Lol another $IBG and $MYSZ soon R/S . Garbage stocks.
0 · Reply
fullFLT
fullFLT Jan. 30 at 5:01 PM
$DRMA I don’t think so….
1 · Reply
Rosedale5
Rosedale5 Jan. 30 at 4:39 PM
$DRMA I can’t take all this winning! Picks have been brutal lately.
0 · Reply
RhlTFSAHG3
RhlTFSAHG3 Jan. 30 at 3:21 PM
$DRMA Only down 6%, this will end up at the Pre-Pump price of a $1.70.
0 · Reply